2. Antibody-drug Conjugate/ADC Related Metabolic Enzyme/Protease
  3. ADC Antibody Carbonic Anhydrase
  4. BAY-79-4620 Antibody

BAY-79-4620 Antibody is a potent and selective CAIX antibody with a human CAIX Kd of 3.6 nM. BAY-79-4620 Antibody yields antibody-drug conjugate (ADC) through conjugating with Monomethyl auristatin E (HY-15162) via a self-immolative enzyme-cleavable linker. BAY-79-4620 Antibody can be used for the research of cervical carcinoma, non-small cell lung carcinoma, breast carcinoma, pancreatic carcinoma, gastric carcinoma, prostate carcinoma.

For research use only. We do not sell to patients.

BAY-79-4620 Antibody

BAY-79-4620 Antibody Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

BAY-79-4620 Antibody Related Antibodies

Top Publications Citing Use of Products

View All Carbonic Anhydrase Isoform Specific Products:

View All Isoforms
CA CA I CA Ⅱ CA IX CA XII CA VII CA VI CA VA CA VB CA XIII CA XIV

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

BAY-79-4620 Antibody is a potent and selective CAIX antibody with a human CAIX Kd of 3.6 nM. BAY-79-4620 Antibody yields antibody-drug conjugate (ADC) through conjugating with Monomethyl auristatin E (HY-15162) via a self-immolative enzyme-cleavable linker. BAY-79-4620 Antibody can be used for the research of cervical carcinoma, non-small cell lung carcinoma, breast carcinoma, pancreatic carcinoma, gastric carcinoma, prostate carcinoma[1].

Species Reactivity

Human
IC50 & Target[1]

hCA IX

3.6 nM (Kd)

In Vitro

BAY-79-4620 Antibody binds selectively to the purified human CAIX ectodomain with a high affinity (Kd = 3.6 nM)[1].
BAY-79-4620 Antibody (25 μg/mL; 1 hour on ice) selectively binds to CAIX-positive PC-3mm2 and MiaPaCa-2-CAIX cells, with no binding to CAIX-negative MiaPaCa-2 cells[1].
BAY-79-4620 Antibody (72 h) potently kills CAIX-positive MiaPaCa-2-CAIX cells with an IC50 of 10 nM via tubulin disruption through conjugating with Monomethyl auristatin E, while CAIX-negative MiaPaCa-2 cells are highly resistant[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BAY-79-4620 Antibody Related Antibodies
Parmacokinetics
Species Dose Route T1/2
Cynomolgus Monkey[1] 2 mg/kg i.v. 255 h
Cynomolgus Monkey[1] 2 mg/kg i.v. 255 h
In Vivo

BAY-79-4620 Antibody (2.5-10 mg/kg; i.v.) dose-dependently inhibits growth of CAIX-positive pancreatic carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (0.625-10 mg/kg; i.v.; 3 doses every 4 days) exhibits potent, dose-dependent antitumor efficacy against HT-29 colorectal carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (0.625-60 mg/kg; i.v.; 3 doses every 4 days) is highly active against HeLa-MaTu cervical carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (i.v.; 3 doses every 4 days) dose-dependently inhibits growth of PC3mm2 prostate carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (60 mg/kg; i.v.; 3 doses every 4 days) exhibits significant antitumor activity against NCI-N87 gastric carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (1-60 mg/kg; i.v.; 3 doses every 4 days) exhibits significant antitumor activity against patient-derived non-small cell lung carcinoma xenografts in NMRI nu/nu mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (0.625-5 mg/kg; i.v.; 3 doses every 4 days) is inactive against multidrug-resistant HCT-15 colorectal carcinoma xenografts in immunocompromised mice after conjugating with Monomethyl auristatin E[1].
BAY-79-4620 Antibody (i.v.; 3 doses every 4 days) antitumor efficacy in immunocompromised mice correlates positively with tumor CAIX expression levels after conjugating with Monomethyl auristatin E[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Immunocompromised mice (8-12 weeks of age)[1]
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.v.
Result: Yielded tumor growth inhibition (TGI) of 63%, 82%, and 94% at doses of 2.5, 5, and 10 mg/kg, respectively.
Produced 100% tumor shrinkage at the 10 mg/kg dose.
Exhibited minimal TGI (≤50%) at 10 mg/kg in mice implanted with CAIX-negative MiaPaCa-2 tumors.
Animal Model: Immunocompromised mice (8-12 weeks of age)[1]
Dosage: 0.625 mg/kg; 1.25 mg/kg; 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.v. 3 doses every 4 days
Result: Yielded transient antitumor activity with single-dose administration.
Produced TGI of 54%, 72%, 97%, 100%, and 100% at doses of 0.625, 1.25, 2.5, 5, and 10 mg/kg with 3 doses every 4 days schedule.
Induced tumor regression in 20% (1.25 mg/kg), 90% (2.5 mg/kg), 100% (5 mg/kg), and 100% (10 mg/kg) of tumors with 3 doses every 4 days schedule.
Showed increased G2/M arrest, multipolar spindles, and decreased tubulin levels by day 1 post-single dose, with near-universal cellular damage by day 5 in the 5 mg/kg group.
Was well tolerated with no weight loss at all doses.
Animal Model: Immunocompromised mice (8-12 weeks of age)[1]
Dosage: 0.625 mg/kg; 1.25 mg/kg; 2.5 mg/kg; 60 mg/kg
Administration: i.v.; 3 doses every 4 days
Result: Showed a minimal effective dose of 0.625 mg/kg.
Caused 80% of tumors to exhibit shrinkage at 1.25 mg/kg.
Induced 100% of tumors to show regression or complete regression at doses ≥2.5 mg/kg.
Produced 10% lethality and 20% body weight loss (maximum tolerated dose) at 60 mg/kg, while all lower doses were well tolerated.
Animal Model: Immunocompromised mice (8-12 weeks of age)[1]
Dosage: 60 mg/kg
Administration: i.v.; 3 doses every 4 days
Result: Produced significant antitumor efficacy.
Animal Model: NMRI nu/nu mice[1]
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg; 60 mg/kg
Administration: i.v.; 3 doses every 4 days
Result: Exhibited significant antitumor efficacy across heterogeneous tumor models (containing both CAIX-positive and CAIX-negative cells), consistent with a bystander effect.
Showed high efficacy in the Lu7406 model.
Animal Model: Immunocompromised mice (8-12 weeks of age)[1]
Dosage: 0.625 mg/kg; 1.25 mg/kg; 2.5 mg/kg; 5 mg/kg
Administration: i.v.; 3 doses every 4 days
Result: Was inactive against HCT-15 tumors, which overexpress P-glycoprotein.
Gene ID

768  [NCBI]

Accession
Target

CA9/CAIX
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

BAY-79-4620 Antibody Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

BAY-79-4620 AntibodyADC AntibodyCarbonic AnhydraseCarbonate dehydrataserenal cell carcinomatubulincervical carcinomanon-small cell lung carcinomaG2/M cell cycle arrestesophageal carcinomaapoptosishuman CAIXcarbonic anhydrase IXmitochondrial CA5Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
BAY-79-4620 Antibody
Cat. No.:
HY-P992322
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.